Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 14INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Esophageal Squamous Cell Carcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Chemotherapy 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

camrelizumab 2Injections 2toripalimab 1epigallocatechin gallate 1atezolizumab 1Zinc 1Tablets 1Quercetin 1Nivolumab 1Metformin 1Imatinib Mesylate 1Gemcitabine 1Everolimus 1Epirubicin 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Triple Negative Breast Neoplasms × toripalimab × Clear all
NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 2 Not yet recruiting
216 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡